Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
Abstract Peripheral T‐cell lymphoma (PTCL) is a heterogeneous disease with poor outcomes. We intend to explore the role of circulating PD‐1 (+) cells in tumor immune evasion in PTCL patients and the mechanism of chidamide as a regulator of immune‐associated medicine on PD‐1 (+) cells. Gene expressio...
Main Authors: | Wei Zhang, Haorui Shen, Yan Zhang, Wei Wang, Shaoxuan Hu, Dongmei Zou, Daobin Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-05-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.2097 |
Similar Items
-
A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL
by: Chong Wei, et al.
Published: (2021-06-01) -
Chidamide in the treatment of peripheral T-cell lymphoma
by: Chan TS, et al.
Published: (2017-01-01) -
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
by: Yuankai Shi, et al.
Published: (2017-03-01) -
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study
by: Wei Zhang, et al.
Published: (2021-08-01) -
Maintenance therapy with chidamide prevents from postoperative recurrence after autologous hematopoietic stem cell transplantation for peripheral T cell lymphoma
by: LIU Hongyun, et al.
Published: (2020-09-01)